Drugs / Acapatamab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04822298 | Aug → Dec 2021 | non-small cell lung carcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03792841 | Feb 2019 → Jun 2023 | castration-resistant prostate carcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04631601 | Jan 2021 → Oct 2023 | prostate carcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | acapatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03792841 ↗ |
| Known as | AMG 160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04822298 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4802258 ↗ |
| Route | Intravenous | “acapatamab is administered intravenously” NCT03792841 ↗ |